Xencor
Xencor and UCLA TDG partner to develop therapeutic antibodies
February 25, 2021Xencor, ucla
Xencor and UCLA Technology Development Group (UCLA TDG) have announced an agreement to develop novel therapeutic antibodies, pairing novel targets …
FDA halts Xencor’s acute myeloid leukaemia trial following two patient deaths
February 21, 2019Research and Development Cancer, FDA, Xencor, leukaemia, pharma
Cancer biopharma firm Xencor has revealed it is to place a hold on its ongoing Phase 1 trial of XmAb14045, …
Novartis signs $150 million deal with Xencor to develop bispecific antibodies
June 28, 2016Manufacturing and Production, Research and Development, Sales and Marketing Cancer, Novartis, Xencor, bispecific antibodies, deal, drug development, drug trial
Swiss drugmaker Novartis (VTX: NOVN) said it has signed a $150 million upfront collaboration and licensing agreement with Xencor to …
Amgen joins M&A rush with deals for Dezima and Xencor
September 16, 2015Research and Development, Sales and Marketing Amgen, Cancer, Denzime, Xencor, cardiovascular disease, high cholesterol, inflammation
Amgen has struck deals that could potentially be worth $3.25 billion, to purchase the Dutch firm Dezima and kick-off a …
Latest content
Aiforia deal to expand access to pathology AI
October 22, 2026
SMC accepts atogepant for acute migraine treatment in Scotland
October 22, 2026
New CCO Ogburn joins Cori Clinical
October 21, 2026
Claris reports visual acuity gains with experimental LSCD treatment
October 21, 2026
